IU team studying NF1 receives renewal for $11.4M SPORE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

An Indiana University research team led by Wade Clapp received renewal for an $11.4 million SPORE grant first awarded by NCI in 2015, supporting research into identifying new treatments for tumors that develop in neurofibromatosis type 1 (NF1), the most common inherited syndrome causing a predisposition to cancer. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

NIH has until Feb. 20 to comply with a congressional subpoena that directs NIH Director Monica Bertagnolli to produce internal documents, including reports and whistleblower complaints that could shed light on whether NIH is adequately responding to complaints of workplace misconduct and sexual harassment. 

Login